Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2026)
Janux Therapeutics' (JANX) quarterly Income from Continuing Operations came in at 52860000.0 in Q1 2026, up 65.83% year-on-year from 31876913.74 in Q1 2025, and down 65.47% on a QoQ basis from 31946000.0 in Q4 2025.
Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Income from Continuing Operations data on file, last reported at 52860000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 65.83% year-over-year to 52860000.0 in Q1 2026; TTM through Mar 2026 was 348498000.0, a 56.94% increase from a year earlier, with the FY2025 full-year figure at 143221000.0, up 66.74% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 52860000.0, down from 31946000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for JANX reached as high as 11758000.0 in Q4 2023 and fell as low as 341545000.0 in Q3 2024.
- Historically, Income from Continuing Operations has averaged 102802235.29 across 5 years, with a median of 54414000.0 in 2022.
- Across the five-year window, Income from Continuing Operations slumped 2020.58% in 2022 and jumped 65.83% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 16409000.0 in 2022, then increased by 28.34% to 11758000.0 in 2023, then plunged by 71.93% to 20216000.0 in 2024, then plunged by 58.02% to 31946000.0 in 2025, then slumped by 65.47% to 52860000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 52860000.0 in Q1 2026, 31946000.0 in Q4 2025, and 131157000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Janux Therapeutics | 964.43 Mn | 964.43 Mn | - | -52.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.86 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -131.16 Mn |
| Jun 30, 2025 | -132.54 Mn |
| Mar 31, 2025 | -154.68 Mn |
| Dec 31, 2024 | -20.22 Mn |
| Sep 30, 2024 | -341.55 Mn |
| Jun 30, 2024 | -292.84 Mn |
| Mar 31, 2024 | -268.52 Mn |
| Dec 31, 2023 | -11.76 Mn |
| Sep 30, 2023 | -26.64 Mn |
| Jun 30, 2023 | -54.12 Mn |
| Mar 31, 2023 | -54.89 Mn |
| Dec 31, 2022 | -16.41 Mn |
| Sep 30, 2022 | -54.41 Mn |
| Jun 30, 2022 | -54.68 Mn |
| Mar 31, 2022 | -48.43 Mn |
| Dec 31, 2021 | -13.42 Mn |
| Sep 30, 2021 | -83.44 Mn |
| Jun 30, 2021 | -6.21 Mn |